



Promoting the appropriate use,
and reducing the abuse and misuse, of monitored drugs in Nova Scotia.

Important Information for Pharmacists

Changes to Compound PINs

As communicated in the January 2014 bulletin, the NSPMP has created new compound PINs for all in-use compounds and registered them with OPINIONS. These new PINs comply with the DIS requirements.

In an effort to ensure consistent compound claims information is submitted, the NSPMP is requesting that all NS pharmacies use the new OPINIONS PINs.

When submitting claims for compounds which include one or more monitored ingredient, pharmacies must record the following information:

- A free text description of the compound; and
- The monitored drug ingredient(s) represented by
 - The name of the ingredient
 - The ID# - either the DIN of the monitored drug manufactured product or the OPINIONS PIN of the monitored drug chemical used in the compound; and
 - The quantity of ingredient used in the compound. For methadone compounds, the quantity dispensed shall be specified in milligrams (mg).

Non-monitored ingredients may also be listed, but are not required.

A non-monitored ingredient can be represented by an ID# that is a DIN, NPN, OPINIONS PIN or pseudo DIN.

NSPMP Monitored Drug Chemical	OPINIONS PIN
Belladonna Tincture	99099966
Cocaine Powder	99099974
Codeine Powder	99099975
Dexedrine Trial	99099976
DHEA (prasterone)	99099977
*Diazepam Powder	99099965
Fentanyl Powder	99099978
Generic Monitored Ingredient	99099979
Hydromorphone Powder	99099980
Ketamine Powder	99099981
Methadone Powder	99099993
Methylphenidate Trial	99099984
*Midazolam Powder	99099964
Morphine Powder	99099986
Sativex Trial	99099991
Testosterone Powder	99099963

***Compound PIN for DIS pharmacy use only**

Inside this Issue

Monitored Drug List Update – Axiron.....	2
Faxing of Duplicate Prescriptions.....	2
eAccess.....	2



Contact Information

PO Box 2200, Halifax NS B3J 3C6
(T): 902.496.7123
(TF) 1.877.476.7767
(F) 902.481.3157
Web: www.nspmp.ca



Monitored Drug List Update – Axiron

Axiron is classified as a monitored drug per the NSPMP Act; therefore, prescribers prescribing this medication must do so on a duplicate prescription. Pharmacy staff shall only dispense Axiron when presented with a duplicate prescription and must ensure that all claims for this medication are submitted online to the NSPMP.

Faxing of Duplicate Prescriptions

The NSPMP Board does not authorize the faxing of duplicate prescriptions; therefore, pharmacies are cautioned against allowing this practice. It is not recommended that pharmacies accept a faxed copy of a duplicate prescription while waiting for an original to be mailed as there have been many instances where the original has not been received.

In situations involving incomplete or incorrect duplicate prescriptions, pharmacists should request the prescriber complete the existing duplicate prescriptions or provide a new one to the patient.

eAccess

Based on generally accepted best practices for limiting the potential for misuse and abuse and/or diversion, the NSPMP strongly recommends that pharmacists register for the NSPMP's eAccess and review each patient's NSPMP claims history prior to dispensing new prescriptions.

The use of eAccess will especially be of value during the transition to the provincial Drug Information System as it is possible that not all monitored prescriptions will be listed in a patient's medication profile in the Drug Information System. However, by checking the NSPMP's eAccess portal, you will be able to view all dispenses for monitored drugs for your patients.

Registering for eAccess involves completion of a registration and user agreement form, which once received by PMP, will be processed within a maximum of 1 business day. Once registration is complete, pharmacists will be issued a unique username and temporary password, sent via two separate emails.

Registration and user agreement forms can be downloaded from the PMP website at <http://www.nspmp.ca/library/00000224-library.pdf> or by calling the Program toll free at 1-877-476-7767 or 902-496-7123 or by email at pmp@medavie.bluecross.ca.